CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer.

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Abstract Text:

D Miotto,P Boschetto,I Bononi,G Milani,C Legorini,G Cavallesco,N Lo Cascio,E Zeni,L M Fabbri,C E Mapp,

Non-small cell lung cancer (NSCLC) shows a particular aggressive behaviour. Tumour associated macrophages (TAMs) play an important role in tumour growth and progression and CC ligand 2 (CCL2)/CCR2 axis is markedly involved in their recruitment in the tumour mass from the circulation. The aim of this study was to determine the plasma levels of CCL2 and the expression of CCR2 in the peripheral blood mononuclear cells (PBMCs) of 18 smokers with NSCLC, eight healthy smokers and nine non-smokers. Then, we investigated CCL2 levels in the supernatants of unstimulated and LPS-stimulated PBMC cultures of the same groups of patients. CCL2 levels in plasma and supernatants of PBMC cultures were determined by ELISA. CCR2 expression in PBMC cytospins was assessed by immunocytochemistry. CCL2 plasma levels and CCR2 expression by PBMCs were similar in patients with NSCLC, healthy smokers and non-smokers. In the supernatants of unstimulated PBMC cultures, CCL2 content was not different between the three groups of subjects. Supernatants of LPS-stimulated PBMCs of NSCLC patients showed a higher content of CCL2 as compared to supernatants of non-smokers (p<0.005). CCL2 content increased 28.5-fold vs baseline production in the group of NSCLC patients, 15-fold in healthy smokers and 13-fold in the group of non-smokers. In conclusion, after LPS stimulation, PBMCs of patients with NSCLC release higher levels of CCL2 as compared to those of non-smokers, supporting the hypothesis of a CCL2 involvement in NSCLC biology.

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Publishing Authors By Initials

D Miotto,P Boschetto,I Bononi,G Milani,C Legorini,G Cavallesco,N Lo Cascio,E Zeni,LM Fabbri,CE Mapp,

For similar behavior and behavior mechanisms: behavior: habits: smoking research abstracts see: behavior and behavior mechanisms: behavior: habits: smoking research

PUBMED ID PMID:

MEDLINE DATE:

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Respiratory medicine

VOLUME: 101

Page Numbers: 1738-43

Journal Abbreviation:

ISSN: 0954-6111

DAY: 12

MONTH: 04

YEAR: 2007

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8908438

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Keywords Mesh Terms:

KEYWORDS: Smoking

MESH TERMS: adverse effects

Chemical & Substance for Abstract: CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Information

Substance Name: Receptors, CCR2

Registry Number: 0

Grant and Affiliation Information for CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer.

AFFILIATION: Department of Clinical and Experimental Medicine, University of Ferrara, 44100 Ferrara, Italy.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Respir Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer Related Publications

• A concise approach to structurally diverse beta-amino acids.
• A phosphorimidate rearrangement for the facile and selective preparation of allylic amines.
• A small molecule transcriptional activation domain.
• Assessing the permissiveness of transcriptional activator binding sites.
• CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer.
• Considerations of the possible aetiology of uterine fibroids.
• Converting inactive peptides into potent transcriptional activators.
• DIGITAL COMPUTER ANALYSIS OF HUMAN ISOTOPIC DRUG KINETICS.
• Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancer.
• Disrupting mediator with a short peptide ligand.
• Mesothelial mediastinal cysts (pericardial cysts); differential diagnosis of shadows continuous with the anterior inferior mediastinum.
• Targeting the transcriptional machinery with unique artificial transcriptional activators.
• Transcriptional up-regulation in cells mediated by a small molecule.
• [3,3]-rearrangements of phosphonium ylides.